Exelixis: all 57 studies

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07845786Phase 2
• Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingNCT07428616Phase 2
• A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07123103Phase 1
• Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)RecruitingNCT06962332Phase 1
• A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsRecruitingNCT06952010Phase 1
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT06943755Phase 2/3
• Study of XB010 in Subjects With Solid TumorsRecruitingNCT06545331Phase 1
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsRecruitingNCT05932862Phase 1
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingNCT05176483Phase 1
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingNCT04446117Phase 3Results posted
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingNCT03690388Phase 3Results posted
• Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCTerminatedNCT01995058Phase 2Results posted
• Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibCompletedNCT01908426Phase 3Results posted
• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerActive, not recruitingNCT01896479Phase 4Results posted
• A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT01865747Phase 3Results posted
• Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100CompletedNCT01605227Phase 3Results posted
• Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerTerminatedNCT01522443Phase 3Results posted
• Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseTerminatedNCT01068782Phase 2Results posted
• Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesCompletedNCT00940225Phase 2Results posted
• Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerCompletedNCT00704730Phase 3Results posted
• Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeCompletedNCT00704288Phase 2Results posted
• A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00596648Phase 1/2Results posted
• A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsTerminatedNCT06630247Phase 1
• Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)TerminatedNCT06191796Phase 1
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06082167Phase 2/3
• Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05678673Phase 3
• Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerActive, not recruitingNCT05425940Phase 3
• Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
• Study of XB002 in Subjects With Solid Tumors (JEWEL-101)CompletedNCT04925284Phase 1
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsActive, not recruitingNCT03845166Phase 1
• Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
• A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal FunctionCompletedNCT01761773Phase 1
• Expanded Access of Cabozantinib in Medullary Thyroid CancerApproved for marketingNCT01683110
• Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced CancerCompletedNCT01553656Phase 1
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsCompletedNCT01493869Phase 1
• A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsCompletedNCT01100619Phase 1
• Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaCompletedNCT00960492Phase 1
• Safety Study of Pharmacokinetics of XL888 in Adults With Solid TumorsTerminatedNCT00796484Phase 1
• Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsWithdrawnNCT00704392Phase 1
• A Phase 1 Study of XL019 in Adults With Polycythemia VeraTerminatedNCT00595829Phase 1
• A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibCompletedNCT00570635Phase 2
• Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesTerminatedNCT00526838Phase 1
• A Safety Study of XL019 in Adults With MyelofibrosisTerminatedNCT00522574Phase 1
• A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced MalignanciesTerminatedNCT00475917Phase 1
• Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaTerminatedNCT00464113Phase 1
• Study of XL418 in Adults With Solid TumorsSuspendedNCT00460278Phase 1
• Study of XL281 in Adults With Solid TumorsCompletedNCT00451880Phase 1
• Study of XL820 Given Orally Daily to Subjects With Solid TumorsCompletedNCT00350831Phase 1
• Safety Study of XL844 in Subjects With Chronic Lymphocytic LeukemiaTerminatedNCT00234481Phase 1
• Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCompletedNCT00215605Phase 1
• Study of XL820 in Adults With Solid TumorsCompletedNCT00129571Phase 1

← Exelixis overview and focus areas